• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Expanding Possibilities

Article

San Francisco - The expanding indications for the topical immune response modulator imiquimod (Aldara) may soon include treatment of superficial basal cell carcinoma (BCC), Mark Naylor, M.D., said at the annual meeting of the American Academy of Dermatology.

Related Videos
Related Content
Colorimetric Scale Offers Practical Classification in Clinical Assessment of Skin of Color

Colorimetric Scale Offers Practical Classification in Clinical Assessment of Skin of Color

Article
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

Podcast
Addressing Disparities in Skin-Aging Prevention Among Women of Color

Addressing Disparities in Skin-Aging Prevention Among Women of Color

Article
ReV Up Your Vitiligo Treatment Strategies

ReV Up Your Vitiligo Treatment Strategies

Podcast
Upadacitinib Outperforms Dupilumab in Primary and Secondary End Points in Head-to-Head AD Study

Upadacitinib Outperforms Dupilumab in Primary and Secondary End Points in Head-to-Head AD Study

Article
Patients With Hidradenitis Suppurativa Have Increased Odds of Respiratory Disease, According to Study Findings

Patients With Hidradenitis Suppurativa Have Increased Odds of Respiratory Disease, According to Study Findings

Article
© 2024 MJH Life Sciences

All rights reserved.